AU4347696A - Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases - Google Patents
Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseasesInfo
- Publication number
- AU4347696A AU4347696A AU43476/96A AU4347696A AU4347696A AU 4347696 A AU4347696 A AU 4347696A AU 43476/96 A AU43476/96 A AU 43476/96A AU 4347696 A AU4347696 A AU 4347696A AU 4347696 A AU4347696 A AU 4347696A
- Authority
- AU
- Australia
- Prior art keywords
- mhc
- prevention
- binding
- treatment
- inflammatory diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94203755 | 1994-12-23 | ||
EP94203755 | 1994-12-23 | ||
PCT/EP1995/005164 WO1996020215A2 (en) | 1994-12-23 | 1995-12-27 | Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU63167/99A Division AU6316799A (en) | 1994-12-23 | 1999-12-06 | Use of MCH-II binding and/or MHC-II mimicking molecules for the prevention and/or treatment of inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4347696A true AU4347696A (en) | 1996-07-19 |
Family
ID=8217495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU43476/96A Abandoned AU4347696A (en) | 1994-12-23 | 1995-12-27 | Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0800534A2 (en) |
JP (1) | JPH10511652A (en) |
CN (1) | CN1171117A (en) |
AU (1) | AU4347696A (en) |
BR (1) | BR9510554A (en) |
CA (1) | CA2208233A1 (en) |
CZ (1) | CZ186897A3 (en) |
HU (1) | HUT77468A (en) |
PL (1) | PL320922A1 (en) |
SK (1) | SK80697A3 (en) |
WO (1) | WO1996020215A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840835A (en) * | 1995-10-30 | 1998-11-24 | Merck & Co., Inc. | Inhibitors of peptide binding to MHC class II proteins |
US5817757A (en) * | 1995-10-30 | 1998-10-06 | Merck & Co., Inc. | Inhibitors of peptide binding to MHO class II proteins |
US5719296A (en) * | 1995-10-30 | 1998-02-17 | Merck & Co., Inc. | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins |
EP0889964A1 (en) | 1996-03-28 | 1999-01-13 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
GB0201896D0 (en) * | 2002-01-28 | 2002-03-13 | Ice Biolog Ltd | Treatment |
HU228957B1 (en) * | 2001-07-02 | 2013-07-29 | Aimsco Ltd | Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response |
CA2473754C (en) * | 2002-01-28 | 2012-04-10 | Aimsco Limited | Treatment of ms with goat serum |
ES2232273B1 (en) * | 2003-03-21 | 2006-07-16 | Jose Manuel Fernandez-Real Lemos | NEW THERAPEUTIC APPLICATIONS OF GLUCOPROTEIN CD14S. |
EP2266606B1 (en) * | 2003-05-15 | 2014-09-10 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3269354D1 (en) * | 1981-06-25 | 1986-04-03 | Univ Leland Stanford Junior | Allele specific immunotherapeutic method and dosage form |
GB8310403D0 (en) * | 1983-04-18 | 1983-05-25 | Mach B F | Cotransformed mouse cells |
EP0204522A3 (en) * | 1985-05-30 | 1987-09-16 | Genetic Systems Corporation | Monoclonal antibody panel for histocompatibility typing |
JPS63275526A (en) * | 1987-05-03 | 1988-11-14 | Hiroshi Okajima | Hiv virus neutralizing antibody |
FR2658197B1 (en) * | 1990-02-14 | 1992-05-22 | Inst Nat Sante Rech Med | RESTRICTED MONOCLONAL ANTIBODIES RECOGNIZING A PEPTIDE ASSOCIATED WITH A MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN - APPLICATIONS TO DIAGNOSIS AND TREATMENT. |
DE4029227A1 (en) * | 1990-09-14 | 1992-03-19 | Imtox Gmbh | MEDICINAL PRODUCT CONTAINING CD14 |
AU3220593A (en) * | 1991-11-19 | 1993-06-15 | Anergen, Inc. | Soluble mhc molecules and their uses |
EP0634935A4 (en) * | 1992-04-06 | 1996-01-31 | North Shore Univ Hospital | A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen. |
ATE223485T1 (en) * | 1992-10-15 | 2002-09-15 | Toray Industries | METHOD FOR PRODUCING RECOMBINANT MHCII PROTEIN IN MICROORGANISMS |
EP0751962B1 (en) * | 1993-05-28 | 2006-08-02 | The Scripps Research Institute | Methods for inhibiting cd14 mediated cell activation |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
-
1995
- 1995-12-27 PL PL95320922A patent/PL320922A1/en unknown
- 1995-12-27 AU AU43476/96A patent/AU4347696A/en not_active Abandoned
- 1995-12-27 CZ CZ971868A patent/CZ186897A3/en unknown
- 1995-12-27 CA CA002208233A patent/CA2208233A1/en not_active Abandoned
- 1995-12-27 WO PCT/EP1995/005164 patent/WO1996020215A2/en not_active Application Discontinuation
- 1995-12-27 HU HU9800269A patent/HUT77468A/en unknown
- 1995-12-27 BR BR9510554A patent/BR9510554A/en not_active Application Discontinuation
- 1995-12-27 SK SK806-97A patent/SK80697A3/en unknown
- 1995-12-27 EP EP95942207A patent/EP0800534A2/en not_active Withdrawn
- 1995-12-27 JP JP8520220A patent/JPH10511652A/en active Pending
- 1995-12-27 CN CN95196985A patent/CN1171117A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PL320922A1 (en) | 1997-11-10 |
SK80697A3 (en) | 1997-12-10 |
JPH10511652A (en) | 1998-11-10 |
CN1171117A (en) | 1998-01-21 |
HUT77468A (en) | 1998-05-28 |
CA2208233A1 (en) | 1996-07-04 |
BR9510554A (en) | 1999-06-29 |
CZ186897A3 (en) | 1998-03-18 |
WO1996020215A2 (en) | 1996-07-04 |
EP0800534A2 (en) | 1997-10-15 |
WO1996020215A3 (en) | 1996-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4172597A (en) | Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications | |
AU2103097A (en) | Cinnoline derivatives and use as medicine | |
AU3897897A (en) | Methods and apparatus for the application of combined fields to disinfect fluids | |
HUP9904361A3 (en) | Use of isobutylgaba and its derivatives for the treatment of pain | |
AU6974996A (en) | Compositions for the treatment of dermatological disorders and methods for their use | |
AU3793697A (en) | Apparatus and methods for the disinfection of fluids | |
AU9403798A (en) | Human regulatory molecules | |
AU4180596A (en) | Functionalised polyorganosiloxanes and one of the processes for the preparation thereof | |
AU3666695A (en) | Pyridazinones and their use as fungicides | |
AU5563398A (en) | Use of mifepristone for the treatment of psychoses and addictive behaviours | |
AU4347696A (en) | Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases | |
AU2387097A (en) | Substituted benzylamines and their use for the treatment of depression | |
AU2821295A (en) | Compositions and methods for the treatment of tumors | |
AU1556497A (en) | Agents for the treatment and prevention of aids | |
AU7448198A (en) | Compositions and means for the treatment of burns and other cutaneous traumas | |
AU5537296A (en) | The use of cross-linked hemoglobin in treating subarachnoid hemorrhage | |
AU6177994A (en) | System for the protection of people and/or property | |
ZA958558B (en) | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | |
AU2154695A (en) | Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof | |
AU2705495A (en) | Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory | |
AUPM885894A0 (en) | Therapeutic molecules | |
AU8049098A (en) | Composition and methods for the treatment of inflammatory diseases | |
AU7161096A (en) | Compositions and methods for inhibiting the binding of pecam | |
EP0893123A4 (en) | Agent for use in the prevention and treatment of disorders associated with various types of ageing | |
AU1587295A (en) | The treatment of gaseous substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |